Valuation : VolitionRx Limited

Market Cap 7.12M 6.13M 5.75M 5.25M 9.89M 680M 9.92M 68.2M 26.61M 343M 26.71M 26.13M 1.14B P/E 2026 *
-0.24x
P/E 2027 * -0.5x
Enterprise Value 7.12M 6.13M 5.75M 5.25M 9.89M 680M 9.92M 68.2M 26.61M 343M 26.71M 26.13M 1.14B EV / Sales 2026 *
2.86x
EV / Sales 2027 * 1.35x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-10.98%
1 week+7.10%
Current month-37.82%
1 month-47.55%
3 months-84.50%
6 months-88.99%
Current year-91.27%
1 week 0.33
Extreme 0.3269
0.72
1 month 0.33
Extreme 0.3269
0.91
Current year 0.33
Extreme 0.3269
7.73
1 year 0.33
Extreme 0.3269
14.8
3 years 0.33
Extreme 0.3269
27.6
5 years 0.33
Extreme 0.3269
82.8
10 years 0.33
Extreme 0.3269
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/3/26
Concord International, Inc.
OtherCompany 0 0%
17/3/26 Tax

Executive/Senior Manager

5,251 0.0039%
17/3/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-10.98%+7.10%-96.60%-98.17% 7.12M
-3.67%-2.65%+90.08%+310.05% 4.22B
-2.00%-2.77%+261.43%+31.70% 3.74B
-2.38%+4.28%+47.31%+76.13% 3.64B
-3.50%+3.52%+283.83%+467.95% 2.71B
-3.09%-9.73%-27.62%-23.20% 2.33B
+5.52%+3.18%+32.26% - 1.5B
-5.91%-8.85%+230.88%-23.69% 1.25B
+11.76%+14.08%+37.91%+65.05% 1.05B
-2.87%+20.89%+26.40%+178.15% 694M
Average -1.72%+3.61%+88.59%+109.33% 2.11B
Weighted average by Cap. -1.77%+2.31%+124.38%+156.81%

Financials

2026 *2027 *
Net sales 2.49M 2.15M 2.01M 1.84M 3.46M 238M 3.47M 23.87M 9.31M 120M 9.35M 9.15M 398M 5.27M 4.54M 4.26M 3.88M 7.32M 503M 7.34M 50.48M 19.7M 254M 19.77M 19.34M 843M
Net income -21.62M -18.63M -17.47M -15.95M -30.04M -2.07B -30.14M -207M -80.87M -1.04B -81.19M -79.42M -3.46B -18.42M -15.87M -14.88M -13.58M -25.59M -1.76B -25.67M -177M -68.89M -889M -69.15M -67.65M -2.95B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
29/08/26 USD 0.4460 -10.98% 13,276,447
27/08/26 USD 0.5010 +47.70% 354,110,921
26/08/26 USD 0.3392 -11.80% 62,421,511
25/08/26 USD 0.3846 -1.64% 568,103
24/08/26 USD 0.3910 -6.21% 1,132,696
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5010USD
Average target price
16.57USD
Spread / Average Target
+3,206.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock